Aptinyx Inc. is a clinical-stage biopharmaceutical company discovering and developing transformative therapies for challenging disorders of the brain and nervous system. Our proprietary NMDA receptor modulator discovery platform enables a differentiated approach to developing novel therapeutic solutions across numerous CNS disorders. We are currently evaluating compounds from our platform in clinical development across cognitive impairment, post-traumatic stress disorder (PTSD), and opioid use disorder (OUD).